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Abstract
Marfan syndrome, a human disease involving cardiovascular and skeletal apparatuses and ocular and central nervous systems, is
associated to mutations in FBN1 gene; heterozygous mutations in TGFBR2 and TGFBR1 genes were found associated to MFS type 2,
characterized by the presence of skeletal and cardiovascular major criteria and absence of eye major criterion.
We screened the TGFBR1 gene in 46 Marfan patients in whom mutations in FBN1 and TGFBR2 genes were excluded and the analysis of
Ex1 was extended to additional 114 Marfan patients and 237 controls.
We detected two potentially pathological sequence variants: the TGFBR1 6Ala allele whose frequency was higher in the group of Marfan
patients (0.13) than in the controls (0.08) (p=0.013; OR=1.69) and an insertion of 20 nucleotides in the 5′UTR that turned out to be a
familial silent rare polymorphism. We hypothesize that TGFBR1 sequence variants may act not only as major, but also as low penetrance
alleles of the clinical phenotype in Marfan syndrome.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: TGFBR1; Marfan syndrome; MFS type 2; TGFBR1 6Ala allele
Marfan syndrome (MFS;MIM#154700) is a multisystemic
dominantly inherited connective tissue disorder with a
prevalence of 1 in 5000–10000 [1]; MFS is mostly caused
by mutations in fibrillin-1 (FBN1;MIM#134797;chr.15q21.1)
[2]. MFS type 2 (MFS2;MIM#154705) is characterized by
absence of major ocular involvement; it has been recently
associated to heterozygous dominant mutations in both
TGFBR2 (MIM#190182;chr.3p22) [3–5], and TGFBR1
(MIM#190181;chr.9q33-34) [4,5], the two genes coding for
the receptors of transforming growth factor beta (TGFβ).
TGFβ induces extracellular matrix (ECM) formation by
binding to its two receptors and by activating the intracellular
signalling through SMAD proteins [6]. Mutations in FBN1,
TGFBR1 and TGFBR2 lead to altered TGFβ signalling
resulting in degenerative changes of the ECM and causing
aneurysms and dissections of the vessel wall in MFS2 [3,7],
Thoracic Aortic Aneurysms and Dissections (TAAD;
MIM#608967) [4,7], and Loeys–Dietz syndrome (LDS;
MIM#609192) [5,8,9]. Noteworthy, in a mouse model of
MFS, excessive TGFβ signalling was demonstrated to
contribute to the formation of aortic aneurysms; furthermore,
treatment with TGFβ antagonists was shown to block and
reverse the demolition of ECM and consequentially the
dilatation and dissection of aorta [10].
We investigated 46 MF patients (34 men and 12 women,
median age 32.5 years, range 7–54 years) diagnosed according
to Ghent criteria, referred to the Center for Marfan Syndrome
and Related Disorders of the Azienda Ospedaliero-Universi-
taria, Careggi, University of Florence.
DNA mutation analysis of FBN1 [11], TGFBR2 [3] and
TGFBR1 genes (Table 1) was performed [11,12]. Clinical
characteristics and molecular data of these patients (8 of
them with MFS2) are shown in Table 2. No mutations in
both FBN1 and TGFBR2 were found. We detected two
potentially pathological mutations both in exon 1 of
TGFBR1. In order to verify their pathogenicity, we ex-
tended the analysis to 114 Marfan patients (69 men and 45
women, median age 35.5 years, range 7–70 years; 18
MFS2, 103 carrying a mutation in FBN1) and 237 healthy
unrelated controls (111 men and 126 women, median age
51.2 years, range 15–91 years) with primers Ex1ins and
Ex1-9⁎ (Table 1). The different alleles were separated on a
4% agarose gel. Patients and controls, all Italian, gave their
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Table 1
Primers of TGFBR1 gene
TGFBR1 gene Forward Reverse TM Size (bp)
EX1 5′-agc agt tac aaa ggg ccg g-3′ 5′-gcg cca tgt ttg aga aag ag-3′ 60 °C 313
EX1ins 5′-gga cgc gcg tcc tcc gag c-3′ 5′-gac cgc cgc ctc cat ggt c-3′ 62 °C 157
EX1-9⁎ 5′-gac cat gga ggc ggc ggt c-3′ 5′-gtc gcc ccc ggg agc ag-3′ 62 °C 99
EX2 5′-gag caa caa aca gtg cat aga aa-3′ 5′-tcc ctt cca gtt cta aaa tca ca-3′ 58 °C 448
EX3 5′-ggc tct ttg gct aag tgg tg-3′ 5′-ttc tag caa gtt ggc tta tta g-3′ 58 °C 449
EX4a 5′-tca gtt ttc tgg gtc act cat t-3′ 5′-gtt ctt ctc tag agg aga ata tc-3′ 58 °C 237
EX4b 5′-gtt tgg aga gga aag tgg c-3′ 5′-gtc tca tct act ttg atg atg g-3′ 56 °C 228
EX5 5′-ttg cag tgt gtg act cag ga-3′ 5′-agg ccc agc ctc cac ctt-3′ 60 °C 351
EX6 5′-ttt ggg ttg gga gaa gag ac-3′ 5′-ttt ggg ttg gga gaa gag ac-3′ 58 °C 399
EX7 5′-tgt ctg aaa gga ggt tca tcc-3′ 5′-aat tct tga aca act tct gct c-3′ 60 °C 256
EX8 5′-gcc ttg gca tta gct gaa taa-3′ 5′-cat tgg ttt gac tgc tat gaa aa-3′ 58 °C 316
EX9a 5′-cgt aaa aat tct tat cca gac c-3′ 5′-cct tct gtt ccc tct cag tg-3′ 60 °C 300
EX9b 5′-ctt cag atc tgc tcc tgg g-3′ 5′-cat tca aag tct gaa tca agg-3′ 60 °C 429
EX9c 5′-gta cat tct cag agg att ctg-3′ 5′-gaa tac caa atg aca tac cac-3′ 60 °C 403
⁎ = primers modified from [13].
Accession number NC_000009.10 for TGFBR1 gDNA.
informed consent and the study was approved by the local
ethics committee of the Faculty of Medicine, University of
Florence.
The 6Ala allele polymorphism in Ex1 (Fig. 1; Table 3a)
[5,13] was a trinucleotide GCG, corresponding to alanine
(Ala), repeated 6 or 9 times. The 6Ala allele was the rare
variant (Fig. 2).
Genotype distribution and allele frequency were in
Hardy–Weinberg equilibrium for the 6Ala allele polymor-
phism both in patients and controls. A 9Ala/7Ala genotype
was detected in one control.
The 6Ala allele frequency significantly differed between the
group of Marfan patients and controls (p=0.013; 0.13vs.0.08).
The genotype distribution of the 6Ala allele polymorphism
was higher in the group of Marfan patients (9Ala/6Ala 21.9%
and 6Ala/6Ala 2.5%) than in the controls (9Ala/6Ala 16%).
Furthermore, the homozygous genotype 6Ala/6Ala was
detected only in 4 MF patients (Table 3b). The odds ratio
was 1.69 (95%CI:1.023–2.785), suggesting that the 6Ala
allele may contribute to Marfan syndrome phenotype.
The 6Ala allele frequency was 0.13 in both classic MFS
and MFS2, although the second group is still too small.
No significant different distribution of the 6Ala allele was
found between genres and between single systems or organs'
involvement.
The heterozygous insertion of 20nts in Ex1-5′UTR
(Fig. 1; Table 3a) was identified in the proband, his
healthy son, and an affected niece of one Marfan family. It
was a duplication of 20nts (nts 3–22), inserted between
nts 22 and 23 of exon 1, 55nts before the ATG start of
protein translation. It is located in a sequence that does not
seem to contain any site for transcription binding proteins
Fig. 1. Sequence variants found in Exon 1 of TGFBR1: A: insertion of the 20 duplicated nucleotides in the Ex1-5′UTR; B: the TGFBR1 6Ala allele is indicated
and the 9nts (3Ala) deleted in the polymorphism are highlighted. Nts = nucleotides; AA = aminoacids; Ala = alanine.
Fig. 2. PCR fragments of homozygous and heterozygous genotypes of TGFBR1
6Ala allele polymorphism and homozygous genotype of normal TGFBR1 9Ala
allele on agarose gel (4%). Lanes 1 and 6 = molecular markers; lanes 2 and 5 =
9Ala/9Ala genotype; lane 3 = 9Ala/6Ala genotype; lane 4 = 6Ala/6Ala
genotype. 9Ala = 319 bp; 6Ala = 310 bp. Ala = alanine; bp = base pairs.
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Table 2
Clinical manifestations and mutations found in 46 Marfan patients
Age
(yrs)
Sex Major criteria Minor criteria
Familial history CV Ocular Skel Skin Pneum TGFBR1 6Ala genotype
1 36 F + − + + + − 9Ala/9Ala
2 35 M + + − − + − 9Ala/9Ala
3 38 M − § + − + − − 9Ala/9Ala
4 42 M − ⁎ + − − + − 9Ala/9Ala
5 46 M − ⁎ + − − + − 9Ala/9Ala
6 46 F − + + + + − 9Ala/9Ala
7 40 M − § + − + + − 9Ala/9Ala
8 11 M − + + − − − 9Ala/9Ala
9 34 F + § + − + + − 9Ala/6Ala
10 24 M − § + − + + + 9Ala/9Ala
11 8 M − + + − − − 9Ala/9Ala
12 23 F + § + − + + − 9Ala/9Ala
13 44 M + + − − + − 9Ala/9Ala
14 13 M + + + + − − 9Ala/9Ala
15 30 M + + − − + − 9Ala/9Ala
16 42 M + + − − + − 9Ala/9Ala
17 40 M + + + − + − 9Ala/9Ala
18 33 F + + + − − − 9Ala/9Ala
19 36 M + + − − + − 9Ala/6Ala
20 42 M − § + − + + − 9Ala/6Ala
21 25 F + − − + + − 9Ala/9Ala
22 22 M − + + − + − 9Ala/9Ala
23 34 F − + + − − − 9Ala/9Ala
24 30 M − ⁎ + − − + − 9Ala/9Ala
25 34 F − + + − − − 9Ala/9Ala
26 42 M − + + − − − 9Ala/9Ala
27 30 M − ⁎ + − − + − 9Ala/9Ala
28 44 M + + − − + − 9Ala/9Ala
ins 20nts hetero
29 45 M + + − − + − 9Ala/9Ala
30 32 M − ⁎ + − − + − 9Ala/9Ala
31 33 F − ⁎ + − − + − 9Ala/6Ala
32 40 M − ⁎ + − − + − 9Ala/9Ala
33 45 M − ⁎ + − − + − 9Ala/9Ala
34 39 F − ⁎ + − − + − 9Ala/6Ala
35 20 F − + + − + − 9Ala/9Ala
36 15 M − ⁎ + − − + − 9Ala/6Ala
37 40 M − ⁎ + − − + − 9Ala/9Ala
38 9 M − + + − − − 9Ala/9Ala
39 28 M − ⁎ + − − + − 9Ala/9Ala
40 25 M + + − − + − 9Ala/9Ala
41 7 M − § + − + − − 9Ala/9Ala
42 32 M + + − − + − 9Ala/9Ala
43 54 F − § + − + + − 9Ala/9Ala
44 44 M + + + − + − 9Ala/9Ala
45 22 M + + − − + − 6Ala/6Ala
46 43 M + + + + + − 9Ala/6Ala
Wt = wild type; yrs = years; M = male; F = female; CNS = central nervous system; CV = cardiovascular system; skel = skeletal system; Pneum = pneumothorax;
⁎ = presence of dural ectasia, required for diagnosis of Marfan; § = diagnosis of MFS2. Data in bold indicates patients with the polymorphism.
nor translational regulatory sequences; therefore, this may
be considered a “silent” and private rare polymorphism.
The frequencies of three known polymorphisms appeared
to be higher in patients than in controls (Table 4).
In vitro studies on TGFβ type I receptor showed that the
molecular differences between 6Ala and 9Ala are due to
altered 6Ala signal sequence; this mechanism may result
either from direct transcriptional inactivation or from
alterations of TGFβ signalling pathways [14]. The 6Ala
signal sequence could directly interact with regulatory
elements of the signalling pathway genes [14].
A highly significant association between the 6Ala allele
of TGFBR1 gene and patients with Marfan syndrome is here
demonstrated for the first time; moreover, homozygosity for
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Table 3a
Modifier mutations in TGFBR1 gene in Marfan patients and healthy controls
EX/IVS Position (nt) Status Patients (n=160) Genotype distribution Controls (n=237) Genotype distribution
Ex1-5′UTR ins 20nts (22/23) Novel Hetero 1 ins=0.006 0 ins=0
Ex1 del 9nts (146-154) Known a Homo 4 6Ala/6Ala=0.025 0 9Ala/6Ala=0.16 b
Hetero 35 9Ala/6A=0.219 38
a [13].
b Frequency from literature (9Ala/6A=0.14).
Table 3b
TGFBR1 6Ala genotype distribution and allele frequency in MFS patients versus controls
Genotype distribution MFS patients (n=160) Controls (n=237) p
TGFBR1 6Ala polymorphism
9Ala/9Ala 121 (75.6%) 199 (84.0%)
9Ala/6Ala 35 (21.9%) 38 (16.0%)
6Ala/6Ala 4 (2.5%) 0 0.014 a




Polymorphisms in TGFBR1 gene in Marfan patients and healthy controls
EX/IVS Position (nt) Status Patients (n=46) Genotype distribution Controls (n=92) Genotype distribution
IVS7 +24 GNA Novel Hetero 16 A=0.35 26 A=0.28
IVS8 del 5nts+(90–94) Novel Hetero 16 del=0.35 25 del=0.27
Ex9-3′UTR +69 ANG Known a Hetero 13 G=0.28 25 G=0.27
nt = nucleotide; ins = insertion; del = deletion.
a [5].
the 6Ala allele was found only in patients. For this reason, at
the moment it may be defined as a low penetrance allele. A
larger number of patients is required to investigate the
possibility that 6Ala allele may act as modifier mutation.
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